

SPECIALTY GUIDELINE MANAGEMENT

MOZOBIL (plerixafor)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Non-Hodgkin's Lymphoma (NHL)

Authorization of 6 months may be granted for the treatment of NHL when ALL of the following criteria are met:

1. Mozobil will be used to mobilize hematopoietic stem cells for collection prior to autologous transplantation
2. Mozobil will be used in combination with G-CSF (e.g., filgrastim, pegfilgrastim)

B. Multiple Myeloma

Authorization of 6 months may be granted for the treatment of multiple myeloma when ALL of the following criteria are met:

1. Mozobil will be used to mobilize hematopoietic stem cells for collection prior to autologous transplantation
2. Mozobil will be used in combination with G-CSF (e.g., filgrastim, pegfilgrastim)

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

IV. REFERENCES

1. Mozobil [package insert]. Cambridge, MA: Genzyme Corporation; October 2015.
2. The NCCN Drugs & Biologics Compendium™ © 2015 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed December 02, 2016.
3. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed December 12, 2016.
4. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed December 12, 2016.
5. Sergio G, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. *Biol Blood Marrow Transplant*. 2014; 20(3):295-308.